CL2009000557A1 - Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos - Google Patents

Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos

Info

Publication number
CL2009000557A1
CL2009000557A1 CL2009000557A CL2009000557A CL2009000557A1 CL 2009000557 A1 CL2009000557 A1 CL 2009000557A1 CL 2009000557 A CL2009000557 A CL 2009000557A CL 2009000557 A CL2009000557 A CL 2009000557A CL 2009000557 A1 CL2009000557 A1 CL 2009000557A1
Authority
CL
Chile
Prior art keywords
active principle
solid preparation
methylacrylate
fine granules
methacrylic acid
Prior art date
Application number
CL2009000557A
Other languages
English (en)
Inventor
Kurasawa Takashi
Watanabe Yasuko
Omachi Yoshihiro
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40791576&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000557(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2009000557A1 publication Critical patent/CL2009000557A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La solicitud 200900557 presenta a una preparación sólida de desintegración oral que comprende gránulos finos que muestran una liberación controlada de un principio activo para uso farmacéutico, en donde los gránulos finos consisten de un gránulo central que comprende el principio activo, una capa intermedia, una a tres capas de recubrimiento que comprende un polímero entérico que comprende al menos un copolímero de ácido metacrílico–metilacrilato-metilmetacrilato, y una capa externa. La preparación sólida de desintegración oral además comprende un aditivo derivado de un alcohol de azúcar (polialcohol) y un desintegrante (que se mezclan con los gránulos para preparar comprimidos de desintegración oral).
CL2009000557A 2008-03-11 2009-03-10 Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos CL2009000557A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008061673 2008-03-11
JP2008334920 2008-12-26

Publications (1)

Publication Number Publication Date
CL2009000557A1 true CL2009000557A1 (es) 2010-10-01

Family

ID=40791576

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000557A CL2009000557A1 (es) 2008-03-11 2009-03-10 Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos

Country Status (26)

Country Link
US (2) US9241910B2 (es)
EP (1) EP2254556A2 (es)
JP (1) JP5604304B2 (es)
KR (1) KR20100129761A (es)
CN (2) CN104127368A (es)
AR (1) AR070863A1 (es)
AU (1) AU2009224254A1 (es)
BR (1) BRPI0909439A2 (es)
CA (1) CA2717947C (es)
CL (1) CL2009000557A1 (es)
CO (1) CO6321224A2 (es)
CR (1) CR11709A (es)
DO (1) DOP2010000273A (es)
EA (1) EA021792B1 (es)
EC (1) ECSP10010538A (es)
GE (1) GEP20135845B (es)
IL (1) IL207989A0 (es)
MA (1) MA32174B1 (es)
MX (1) MX2010009824A (es)
MY (1) MY173730A (es)
NZ (1) NZ588407A (es)
PE (2) PE20141034A1 (es)
TW (1) TWI441658B (es)
UY (1) UY31698A (es)
WO (1) WO2009113703A2 (es)
ZA (1) ZA201006679B (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104127368A (zh) 2008-03-11 2014-11-05 武田药品工业株式会社 口腔崩解固体制剂
WO2009158368A1 (en) * 2008-06-26 2009-12-30 Mcneil-Ppc, Inc. Coated particles containing pharmaceutically active agents
US8303868B2 (en) 2009-01-26 2012-11-06 Shin-Etsu Chemical Co., Ltd. Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
EP2319504A1 (en) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
US20130216617A1 (en) * 2010-06-29 2013-08-22 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
EA028217B1 (ru) * 2010-12-27 2017-10-31 Такеда Фармасьютикал Компани Лимитед Разрушающаяся во рту таблетка (варианты)
CN102716097A (zh) * 2012-05-29 2012-10-10 浙江华海药业股份有限公司 控制口腔崩解片药物释放速率的方法
FI126168B (en) 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
JP6539274B2 (ja) 2013-08-12 2019-07-03 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 押出成形された即放性乱用抑止性丸剤
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
ES2700364T3 (es) * 2015-02-10 2019-02-15 Fujifilm Corp Comprimido de disgregación oral y método para su fabricación
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US20190054029A1 (en) * 2016-02-23 2019-02-21 Nipro Corporation Pharmaceutical composition particles, orally disintegrating preparation including same, and method for producing pharmaceutical composition particles
GB201607548D0 (en) * 2016-04-29 2016-06-15 Univ Central Lancashire Solid dosage form
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
JP7057287B2 (ja) * 2016-12-28 2022-04-19 富士フイルム富山化学株式会社 医薬組成物
JP7080215B2 (ja) * 2017-02-21 2022-06-03 Ｅａファーマ株式会社 顆粒製剤
JP7235193B2 (ja) * 2017-04-26 2023-03-08 大正製薬株式会社 固形組成物
JP7009288B2 (ja) * 2017-05-18 2022-01-25 エルメッド株式会社 湿製錠剤の製造方法及び湿製錠剤の品質向上方法
JP7336187B2 (ja) * 2017-11-30 2023-08-31 日本ケミファ株式会社 多層構造を有する粒子状医薬組成物
EP3740197A4 (en) 2018-01-16 2021-11-10 Applied Materials, Inc. METAL OXIDE ENCAPSULATED DRUG COMPOSITIONS AND METHODS FOR PREPARATION
MX2020007817A (es) 2018-01-24 2020-09-25 Purdue Pharma Lp Prevención y tratamiento del trastorno del sueño.
TW201940171A (zh) * 2018-02-08 2019-10-16 景凱生物科技股份有限公司 類鴉片受體拮抗劑之固體劑型用之醫藥劑型
SG11202107481TA (en) 2019-01-31 2021-08-30 Purdue Pharma Lp Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
IL297776A (en) 2020-04-30 2022-12-01 Nanocopoeia Llc Orally disintegrating tablets containing an amorphous solid dispersion of nalotinib
CN112121067A (zh) * 2020-11-16 2020-12-25 深圳科兴药业有限公司 一种婴儿型双歧杆菌微胶囊及其制备方法
WO2023182332A1 (ja) * 2022-03-22 2023-09-28 株式会社ダイセル 口腔内崩壊錠用の添加剤組成物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
CA2587022A1 (en) 1998-05-18 1999-11-25 Takeda Pharmaceutical Company Limited Orally disintegrable tablets
WO2000006126A1 (en) 1998-07-28 2000-02-10 Takeda Chemical Industries, Ltd. Rapidly disintegrable solid preparation
EP2266542A3 (en) 1998-10-01 2013-07-31 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TWI289557B (en) 1999-06-17 2007-11-11 Takeda Chemical Industries Ltd A crystal of a hydrate of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
PL201766B1 (pl) 2001-01-31 2009-05-29 Roehm Gmbh Wielocząsteczkowa postać leku zawierająca przynajmniej dwa typy granulek powlekanych w odmienny sposób oraz jej zastosowanie
NZ530511A (en) 2001-07-16 2005-06-24 Astrazeneca Ab A tablet for treating disorders of the gastrointestinal tract comprising a proton pump inhibitor and at least one antacid that has a barrier layer to cover an enteric coating film
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
US20040096497A1 (en) 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
MXPA04010956A (es) 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
EP1651193A2 (en) 2003-07-17 2006-05-03 Dr. Reddy's Laboratories, Inc. Pharmaceutical compositions having a swellable coating
AU2004275835B2 (en) 2003-09-26 2011-06-23 Alza Corporation Controlled release formulations exhibiting an ascending rate of release
GB0323232D0 (en) * 2003-10-03 2003-11-05 Rolls Royce Plc Electrical machine
WO2005079752A2 (en) 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20050181052A1 (en) 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
CN1964704A (zh) 2004-03-03 2007-05-16 特瓦制药工业有限公司 包含酸不稳定药物的稳定药用组合物
WO2005084649A1 (ja) 2004-03-04 2005-09-15 Takeda Pharmaceutical Company Limited 安定なカプセル剤
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
CA2579767A1 (en) * 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
WO2006101536A1 (en) * 2004-11-04 2006-09-28 Akina, Inc. Fast-melting tablets having taste-masking and sustained release properties
WO2006070845A1 (ja) 2004-12-28 2006-07-06 Eisai R & D Management Co., Ltd. 速崩壊性錠剤及びその製造方法
GB0502479D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
FR2885526B1 (fr) 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
DE102005024614A1 (de) 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
CA2614526A1 (en) 2005-07-11 2006-10-12 Nycomed Danmark Aps Benzimidazole formulation
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
WO2007037259A1 (ja) 2005-09-29 2007-04-05 Eisai R & D Management Co., Ltd. 生体内での崩壊性を向上させたパルス製剤
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US20070141151A1 (en) 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
JP2009519334A (ja) 2005-12-20 2009-05-14 テバ ファーマシューティカル インダストリーズ リミティド ランソプラゾール経口崩壊錠剤
WO2007075980A2 (en) 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
EP1967211A4 (en) 2005-12-28 2009-12-30 Takeda Pharmaceutical PROCESS FOR PRODUCING SOLID PREPARATION DISINTEGRATING IN ORAL CAVITY
KR100762847B1 (ko) 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
EP1837016A3 (en) 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
EP2012756A4 (en) 2006-04-20 2013-01-23 Inventia Healthcare Private Ltd MULTI-UNIT COMPOSITIONS
CA2648495C (en) 2006-04-26 2016-07-05 Alphapharm Pty Ltd Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix
WO2007129178A2 (en) 2006-04-28 2007-11-15 Wockhardt Ltd Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor
MX2008016416A (es) 2006-06-19 2009-03-03 Mcneil Ppc Inc Particulas revestidas entericas que contienen un ingrediente activo.
US20090291136A1 (en) 2006-07-11 2009-11-26 Lek Pharmaceuticals D.D. Multiple Unit Tablets
RU2009106681A (ru) 2006-07-28 2010-09-10 Др.Редди`С Лабораторис Лтд. (In) Гранулированные фармацевтические композиции
CA2662123C (en) 2006-08-30 2015-12-01 Jagotec Ag Controlled release oral dosage formulations comprising a core and one or more barrier layers
US9486446B2 (en) * 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
EP2152250B1 (en) 2007-05-07 2019-09-04 Evonik Röhm GmbH Solid dosage forms comprising an enteric coating with accelerated drug release
CN104127368A (zh) 2008-03-11 2014-11-05 武田药品工业株式会社 口腔崩解固体制剂
US20100015239A1 (en) 2008-07-17 2010-01-21 Ahmed Salah U Orally Disintegrating Solid Pharmaceutical Dosage Forms Comprising Delayed-Release Lansoprazole and Methods of Making and Using the Same
EA028217B1 (ru) 2010-12-27 2017-10-31 Такеда Фармасьютикал Компани Лимитед Разрушающаяся во рту таблетка (варианты)

Also Published As

Publication number Publication date
TWI441658B (zh) 2014-06-21
MA32174B1 (fr) 2011-03-01
WO2009113703A2 (en) 2009-09-17
BRPI0909439A2 (pt) 2015-12-15
EA021792B1 (ru) 2015-09-30
CA2717947C (en) 2020-07-07
US20150037423A1 (en) 2015-02-05
ZA201006679B (en) 2011-11-30
AU2009224254A1 (en) 2009-09-17
US9241910B2 (en) 2016-01-26
KR20100129761A (ko) 2010-12-09
MY173730A (en) 2020-02-18
AU2009224254A2 (en) 2010-11-18
EP2254556A2 (en) 2010-12-01
GEP20135845B (en) 2013-06-10
ECSP10010538A (es) 2010-11-30
CA2717947A1 (en) 2009-09-17
JP2011513204A (ja) 2011-04-28
US20110091563A1 (en) 2011-04-21
PE20141034A1 (es) 2014-09-10
CR11709A (es) 2010-11-04
CO6321224A2 (es) 2011-09-20
JP5604304B2 (ja) 2014-10-08
NZ588407A (en) 2012-07-27
WO2009113703A3 (en) 2010-06-17
AR070863A1 (es) 2010-05-12
MX2010009824A (es) 2010-09-28
IL207989A0 (en) 2010-12-30
CN102026627A (zh) 2011-04-20
EA201071054A1 (ru) 2011-04-29
CN104127368A (zh) 2014-11-05
DOP2010000273A (es) 2010-09-30
UY31698A (es) 2009-11-10
TW200944249A (en) 2009-11-01
PE20091620A1 (es) 2009-11-12
CN102026627B (zh) 2016-10-26

Similar Documents

Publication Publication Date Title
CL2009000557A1 (es) Preparacion solida de desintegracion oral de liberacion controlada de un principio activo, tal como lansoprazol, que comprende granulos finos que comprenden una capa de recubrimiento que contiene un copolimero de acido metacrilico–metilacrilato–metilmetacrilato, y tienen un tamaño de partícula promedio de 500 µm o menos
CL2013001793A1 (es) Comprimido de desintegracion oral de liberacion controlada que comprende i) granulos que contienen lanzoprazol y una capa de recubrimiento que comprende un copolimero y ii) granulos que comprenden lanzoprazol y una capa de recubrimiento que comprende un copolimero y un polimero, con granulos de tamaño medio de no mas de 500 µm.
UY33062A (es) Comprimidos y composiciones farmacéuticas comprimibles recubiertos y métodos de fabricación
CL2013001586A1 (es) Composicion microgranular de rapida dispersion que comprende al menos un alcohol de azucar, un sacarido, o una mezcla de estos, al menos un super disgregante y al menos un aditivo multifuncion; comprimido de desintegracion oral que comprende la composicion microgranular y al menos un principio activo; y metodos de fabricacion.
AR069905A1 (es) Formulacion de liberacion controlada, preventiva de mal uso, en donde el agente farmaceuticamente activo es un farmaco con capacidad de abuso
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
WO2008146178A3 (en) A novel tablet dosage form
WO2011084593A3 (en) Abuse-resistant formulations
CO6300931A2 (es) Composiciones farmaceuticas que comprenden particulas de liberacion controlada con un nucleo que comprende farmacos levemente basicos
NO20091501L (no) Farmasoytiske sammensetninger
CL2015000893A1 (es) Formulación de una forma farmacéutica sólida de desintegración rápida que comprende carbonato de calcio funcionalizado, un ingrediente activo y por lo menos un desintegrante; y método para su fabricación.
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
MY147641A (en) Fast release paracetamol tablets
WO2013158814A8 (en) Immediate release, abuse deterrent pharmaceutical compositions
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
WO2011106416A3 (en) Abuse-resistant formulations
WO2007143155A3 (en) Sustained release pharmaceutical dosage form containing phenylephrine
AR069875A1 (es) Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2009043926A3 (en) Oral fast disintegrating tablets
CL2013003161A1 (es) Composicion farmaceutica en forma de microgranulos de disolucion rapida para administracion vaginal que comprende a) un farmaco vaginalmente activo, b) un excipiente polimerico, c) un alcohol de azucar, sacarido o una mezcla de los mismos; procedimiento de preparacion.
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
WO2010127205A3 (en) Fixed dose drug combination formulations
WO2011111027A3 (en) Oral dispersible delayed release tablet formulation